Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models

The most common dominantly inherited ataxia, spinocerebellar ataxia type 3 (SCA3), is an incurable neurodegenerative disorder caused by a CAG repeat expansion in the ATXN3 gene that encodes an abnormally long polyglutamine tract in the disease protein, ATXN3. Mice lacking ATXN3 are phenotypically no...

Full description

Bibliographic Details
Main Authors:	Lauren R. Moore, Gautam Rajpal, Ian T. Dillingham, Maya Qutob, Kate G. Blumenstein, Danielle Gattis, Gene Hung, Holly B. Kordasiewicz, Henry L. Paulson, Hayley S. McLoughlin
Format:	Article
Language:	English
Published:	Elsevier 2017-06-01
Series:	Molecular Therapy: Nucleic Acids
Subjects:	antisense oligonucleotide ASO ATXN3 spinocerebellar ataxia type 3 SCA3 polyglutamine disease Machado-Joseph disease MJD
Online Access:	http://www.sciencedirect.com/science/article/pii/S2162253117301555

Similar Items

Pathogenesis of SCA3 and implications for other polyglutamine diseases
by: Hayley S. McLoughlin, et al.
Published: (2020-02-01)

Neurodegenerative phosphoprotein signaling landscape in models of SCA3
by: Anna S. Sowa, et al.
Published: (2021-03-01)

A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats
by: Jana Boy, et al.
Published: (2010-02-01)

Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons, and Axons Reveals Central Molecular Processes and Biomarkers in SCA3/MJD Using Knock-In Mouse Model
by: Kalina Wiatr, et al.
Published: (2021-06-01)

Co‐occurrence of ATXN3 and ATXN2 repeat expansions in Chinese ataxia patients with slow saccades
by: Chao Wu, et al.
Published: (2019-06-01)

Identification and functional dissection of localization signals within ataxin-3
by: Paul Michel Aloyse Antony, et al.
Published: (2009-11-01)

A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD
by: Pawel M. Switonski, et al.
Published: (2015-01-01)

Machado-Joseph Disease: from first descriptions to new perspectives
by: Bettencourt Conceição, et al.
Published: (2011-06-01)

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation
by: An-Hsun Chou, et al.
Published: (2008-07-01)

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3
by: An-Hsun Chou, et al.
Published: (2011-02-01)

Brain stem and cerebellum volumetric analysis of Machado Joseph disease patients
by: S T Camargos, et al.
Published: (2011-01-01)

Toward understanding the role of protein context in the polyglutamine disease, SCA3
by: Harris, Ginny Marie
Published: (2011)

The Truncated C-terminal Fragment of Mutant ATXN3 Disrupts Mitochondria Dynamics in Spinocerebellar Ataxia Type 3 Models
by: Jung-Yu Hsu, et al.
Published: (2017-06-01)

Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3
by: Li Zeng, et al.
Published: (2015-10-01)

Dataset on the effect of Rubicon overexpression on polyglutamine-induced locomotor dysfunction in Drosophila
by: Masaki Oba, et al.
Published: (2021-08-01)

The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples
by: Diana Duarte Lobo, et al.
Published: (2020-08-01)

Chemical Chaperones Reduce Aggregate Formation and Cell Death Caused by the Truncated Machado–Joseph Disease Gene Product with an Expanded Polyglutamine Stretch
by: Hideaki Yoshida, et al.
Published: (2002-07-01)

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein
by: Naila S. Ashraf, et al.
Published: (2020-04-01)

<i>n</i>-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway
by: Jui-Hao Lee, et al.
Published: (2021-06-01)

Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing
by: Craig S. McIntosh, et al.
Published: (2019-10-01)

Occupational therapy in spinocerebellar ataxia type 3: an open-label trial
by: R.C.R. Silva, et al.
Published: (2010-06-01)

Trehalose alleviates the phenotype of Machado–Joseph disease mouse models
by: Magda M. Santana, et al.
Published: (2020-04-01)

A Mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado–Joseph disease-like transgenic mice
by: Veronica F. Colomer Gould, et al.
Published: (2007-09-01)

MR Imaging of SCA3/MJD
by: Na Wan, et al.
Published: (2020-08-01)

Normal ATXN3 allele but not CHIP polymorphisms modulates age at onset in Machado-Joseph Disease
by: Marcondes C. França Jr, et al.
Published: (2012-11-01)

Detection of an Insertion in the ATXN3 Gene in Chronic Myeloid Leukemia Cases Using Exome Sequencing
by: Haider Lafta, et al.
Published: (2021-01-01)

New alternative splicing variants of the ATXN2 transcript
by: Isabel Lastres-Becker, et al.
Published: (2019-07-01)

Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machado–Joseph Disease
by: Adriano M. de Assis, et al.
Published: (2017-09-01)

Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model
by: Judit M. Pérez Ortiz, et al.
Published: (2018-08-01)

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion
by: Anna Niewiadomska-Cimicka, et al.
Published: (2020-06-01)

Is the High Frequency of Machado-Joseph Disease in China Due to New Mutational Origins?
by: Tianjiao Li, et al.
Published: (2019-02-01)

Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
by: Jeannette Hübener, et al.
Published: (2010-04-01)

Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL
by: An-Hsun Chou, et al.
Published: (2006-02-01)

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon
by: Melvin M. Evers, et al.
Published: (2013-10-01)

Metabolic Profiling Reveals Biochemical Pathways and Potential Biomarkers of Spinocerebellar Ataxia 3
by: Zhi-hua Yang, et al.
Published: (2019-06-01)

Spinocerebellar ataxia 7 (SCA7) in Indian population: predilection of ATXN7-CAG expansion mutation in an ethnic population
by: Mohammed Faruq, et al.
Published: (2015-01-01)

STUDIES OF FACTORS AFFECTING INTRACELLULAR TOXICITY OF THE SCA7 DISEASE PROTEIN ATAXIN - 7 : FOCUS ON ATAXIN-7 DEGRADATION AND OXIDATIVE STRESS
by: Yu, Xin
Published: (2011)

Allosteric regulation of deubiquitylase activity through ubiquitination
by: Serena eFaggiano, et al.
Published: (2015-02-01)

Spinocerebellar ataxia type 15 (sca15) maps to 3p24.2-3pter:
by: Melanie A Knight, et al.
Published: (2003-07-01)

Generation of Common Marmoset Model Lines of Spinocerebellar Ataxia Type 3
by: Ikuo Tomioka, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_l33dftngsi4tu3g1enhos991e7